Trial site
Tottori University Hospital
Yonago, Tottori 683-8504, JapanNot linked to an institution yet
- 14running trials
- 3closed trials
The trials here
What the 17 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 1/23 trials
- Status
- Active, not recruiting8 trials
- Recruiting5 trials
- Completed3 trials
- Not yet recruiting1 trial
- Lead sponsor
- Eli Lilly and Company5 trials
- Bayer2 trials
- argenx1 trial
- Canadian Cancer Trials Group1 trial
- Gilead Sciences1 trial
- and 7 more
Running trials
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849· Phase 3· argenx· Source
Contact: Kazuhiko Matsuzawa, MD
Recruiting
MSA-01 in Multiple System Atrophy
NCT07446894· Phase 3· Tokyo University· Source
Contact: Ritsuko Hanajima
Recruiting
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
NCT06890598· Phase 3· Eli Lilly and Company· Source
Contact: Tomohiro Sakamoto (principal investigator)
Recruiting
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212· Phase 3· Rakuten Medical, Inc.· Source
Contact: Kazunori Fujiwara, MD
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· Phase 3· Bayer· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Tomohiro Sakamoto (principal investigator)
Active, not recruiting
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
NCT05983575· Phase 3· Sound Wave Innovation CO., LTD.· Source
Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· Phase 3· Summit Therapeutics· Source
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT04194944· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT03157128· Phase 1/2· Eli Lilly and Company· Source
Recruiting
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116· Phase 1/2· Turning Point Therapeutics, Inc.· Source
Contact: Kodani Masahiro, Site 6606
Active, not recruiting
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623· North East Japan Study Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error